Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0140-6736(90)90471-g | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tacrolimus in the treatment of idiopathic nephrotic syndrome.
Expert Opin Investig Drugs
July 2007
Charité--Campus Benjamin Franklin, Centrum 10--Nephrology, Hindenburgdamm 30, Berlin, Germany.
The immunosuppressant tacrolimus (FK-506) is a calcineurin inhibitor with a widespread use for the prevention of graft rejection in transplantation medicine. Tacrolimus inhibits the activation of an essential transcription factor for the transcription of cytokine genes in T cells leading to a decreased production of cytokines such as IL-2 and IFN-gamma. As T-cell activation plays a crucial role in the pathogenesis of inflammatory glomerular diseases, there is an increasing number of reports on the use of tacrolimus in nephrotic syndrome.
View Article and Find Full Text PDFTacrolimus in steroid-resistant and steroid-dependent nephrotic syndrome.
Clin Nephrol
June 2006
Medical Clinic IV, Nephrology, Charité, Campus Benjamin Franklin, Berlin, Germany.
Background: Steroid resistance and steroid dependence constitute a major problem in the treatment of minimal-change disease and focal segmental glomerulosclerosis (FSGS). Cyclophosphamide and cyclosporine are well-established alternative immunomodulating agents, whereas data on FK 506 (tacrolimus) are rare.
Methods: The present work provides data from 10 patients of an open, monocentric, non-randomized, prospective trial.
[Immunosuppressive therapy for nephrotic syndrome and strategy for adverse side effects from that therapy].
Nihon Rinsho
October 2004
Division of Nephrology, Department of Internal Medicine, Juntendo University, School of Medicine.
The nephrotic syndrome is commonly caused by various glomerulonephritides, i.e. minimal change nephrotic syndrome, focal segmental glomerulosclerosis and membranous nephropathy.
View Article and Find Full Text PDF[Use of Cyclosporine A and new immunosuppressive drugs in the therapy of glomerulonephritis].
Przegl Lek
February 2002
Klinika Nefrologii Collegium Medicum Uniwersytetu Jagiellońskiego w Krakowie.
Multiple clinical trials have been undertaken during last years to assess indications, efficiency and safety of glomerulonephritis treatment with new immunosuppressive drugs as cyclosporine (CsA, Mycophenolate Mophetil (MMF) and Tacrolimus (FK 506). The main indication for cyclosporine is nephrotic syndrome resistance to steroids and cytotoxic agents, steroid-dependent and multi-relapsing cases with serious toxic side effects or with contraindications for steroids and cytotoxic drugs. CsA was administered at the dose of 4-5 mg/kg/day in adults and 5-6 mg/kg/day in children.
View Article and Find Full Text PDFFK 506 and mycofenolate mofetil rescue for acute steroid-resistant and chronic rejection after liver transplantation.
Transplant Proc
November 1997
Department of Surgery, Humboldt University Berlin, Germany.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!